Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.

By P. Richardson, R. Schlossman, E. Weller, T. Hideshima, C. Mitsiades, F. Davies, R. LeBlanc, L. Catley, D. Doss, K. Kelly and 10 more. Blood, 2002

819 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. (2006, background): “Recent studies show that lenalidomide, an analog of thalidomide, may be safer and more effective than thalidomide.(27) A combination trial with lenalidomide plus dexamethasone has already shown improved activity with lower toxicity in a phase II clinical trial.”
The evolution of thalidomide and its IMiD derivatives as anticancer agents (2004, background): “The first completed clinical trial of CC-5013 in relapsed and refractory MM patients was published in 2002 (Ref”
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. (2005, background): “Lenalidomide (CC-5013) is an analogue of thalidomide that has demonstrated significantly more potent preclinical activity compared to thalidomide.(15,16) It has also shown For personal use only.”